Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration. The study aims to compare the safety and pharmacokinetics data to assess feasibility of single-site and multiple-site injection for administration.
Official title: A Single-center, Randomized, Crossover, Open-label Phase I Study to Compare the Safety and Pharmacokinetics of SHR-1209 Given as Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2025-03-14
Completion Date
2025-07
Last Updated
2025-06-24
Healthy Volunteers
Yes
Conditions
Interventions
SHR-1209 single-site subcutaneous injection
SHR-1209 single-site subcutaneous injection.
SHR-1209 multiple-site subcutaneous injections
SHR-1209 multiple-site subcutaneous injections.
Locations (1)
The First Affiliated Hospital of USTC
Hefei, Anhui, China